- Home
- UEC vs ACAD Comparison
UEC vs ACAD Comparison
Compare UEC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UEC
- ACAD
- Stock Information
- Founded
- UEC 2003
- ACAD 1993
- Country
- UEC United States
- ACAD United States
- Employees
- UEC N/A
- ACAD N/A
- Industry
- UEC Other Metals and Minerals
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- UEC Basic Materials
- ACAD Health Care
- Exchange
- UEC Nasdaq
- ACAD Nasdaq
- Market Cap
- UEC 2.8B
- ACAD 2.5B
- IPO Year
- UEC N/A
- ACAD 2004
- Fundamental
- Price
- UEC $6.44
- ACAD $22.71
- Analyst Decision
- UEC Strong Buy
- ACAD Buy
- Analyst Count
- UEC 3
- ACAD 16
- Target Price
- UEC $10.08
- ACAD $27.00
- AVG Volume (30 Days)
- UEC 18.3M
- ACAD 1.6M
- Earning Date
- UEC 06-02-2025
- ACAD 08-05-2025
- Dividend Yield
- UEC N/A
- ACAD N/A
- EPS Growth
- UEC N/A
- ACAD N/A
- EPS
- UEC N/A
- ACAD 1.37
- Revenue
- UEC $66,837,000.00
- ACAD $996,283,000.00
- Revenue This Year
- UEC $41,201.79
- ACAD $13.39
- Revenue Next Year
- UEC $25.78
- ACAD $10.59
- P/E Ratio
- UEC N/A
- ACAD $16.65
- Revenue Growth
- UEC 70.62
- ACAD 22.42
- 52 Week Low
- UEC $3.85
- ACAD $13.40
- 52 Week High
- UEC $8.93
- ACAD $25.23
- Technical
- Relative Strength Index (RSI)
- UEC 56.84
- ACAD 66.04
- Support Level
- UEC $6.46
- ACAD $21.35
- Resistance Level
- UEC $7.15
- ACAD $22.69
- Average True Range (ATR)
- UEC 0.40
- ACAD 0.76
- MACD
- UEC 0.01
- ACAD -0.13
- Stochastic Oscillator
- UEC 53.29
- ACAD 70.76
About UEC Uranium Energy Corp.
Uranium Energy Corp is engaged in uranium mining and related activities. The company is working towards fueling the demand for carbon-free nuclear energy, a key solution to climate change, and energy source for the low-carbon future. The company is advancing its next generation of low-cost, environmentally friendly, in-situ recovery (ISR) mining uranium projects. The company has two extraction-ready ISR hub and spoke platforms in South Texas and Wyoming. UEC also has seven U.S. ISR uranium projects with all of their permits in place, with additional diversified holdings of uranium assets across the U.S., Canada and Paraguay.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.